| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | 
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Total Revenue | 84.74M | 115.61M | 165.96M | 174.19M | 202.71M | 158.41M | 
| Gross Profit | 14.29M | 20.05M | 18.77M | 38.17M | 58.21M | 58.95M | 
| EBITDA | -31.87M | -46.49M | -22.02M | -64.65M | -17.04M | -29.62M | 
| Net Income | -79.37M | -99.67M | -62.38M | -107.46M | -45.12M | -52.11M | 
| Balance Sheet | ||||||
| Total Assets | 138.29M | 151.32M | 231.19M | 293.98M | 415.18M | 429.60M | 
| Cash, Cash Equivalents and Short-Term Investments | 772.00K | 3.00M | 2.03M | 2.20M | 6.95M | 7.43M | 
| Total Debt | 96.22M | 129.63M | 109.99M | 105.91M | 98.47M | 85.01M | 
| Total Liabilities | 200.71M | 188.53M | 168.79M | 172.46M | 181.15M | 146.56M | 
| Stockholders Equity | -62.42M | -37.20M | 62.39M | 121.35M | 233.86M | 283.05M | 
| Cash Flow | ||||||
| Free Cash Flow | 3.08M | -1.08M | 4.65M | -6.53M | -12.29M | 7.75M | 
| Operating Cash Flow | 5.61M | -189.00K | 5.37M | 8.61M | -8.82M | 9.65M | 
| Investing Cash Flow | -2.37M | -742.00K | 13.17M | -16.84M | 872.00K | -2.52M | 
| Financing Cash Flow | -3.02M | 1.91M | -18.69M | 4.78M | 6.02M | -2.91M | 
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth | 
|---|---|---|---|---|---|---|---|
| ― | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
| ― | C$300.89M | 74.67 | 1.86% | ― | 38.86% | ― | |
| ― | C$393.48M | ― | -0.70% | ― | 28.42% | 48.33% | |
| ― | C$406.71M | ― | -45.36% | ― | -12.25% | -47.36% | |
| ― | C$227.80M | ― | ― | ― | -21.73% | 4.03% | |
| ― | C$608.85M | ― | -98.42% | ― | -4.24% | 55.82% | |
| ― | C$213.77M | -2.05 | ― | ― | -40.23% | -5.31% | 
On August 18, 2025, TILT Holdings Inc. announced the closing of the sale of its two Massachusetts dispensaries to In Good Health, a locally owned cannabis company. This transaction, part of TILT’s strategic alternatives review, involved the operation of the Taunton location by In Good Health and the closure of the Brockton dispensary. The purchase price was adjusted to $1.75 million, and Highgate Capital Partners acted as the broker for this transaction.
The most recent analyst rating on (TSE:TILT) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on TILT Holdings Inc stock, see the TSE:TILT Stock Forecast page.
TILT Holdings Inc. reported its second-quarter 2025 results, highlighting a strategic shift towards an asset-light business model focused on Jupiter, its vaporization hardware platform. The company achieved regulatory approval for a dispensary sale in Massachusetts and is pursuing strategic alternatives for its Ohio and Massachusetts assets, marking a planned exit from plant-touching operations. This transition aims to simplify operations and improve capital efficiency. Despite a decrease in revenue due to a shift to a commission-based model and macroeconomic pressures, the company remains confident in its strategy, focusing on innovation and global market expansion.
TILT Holdings reported its second quarter 2025 results, highlighting a strategic shift towards an asset-light business model centered on its Jupiter segment. The company achieved regulatory milestones and is exiting plant-touching operations in Massachusetts and Ohio, aiming to simplify operations and enhance capital efficiency. Despite a decrease in revenue due to a transition to a commission-based model and supply chain challenges, TILT remains focused on expanding its vaporization hardware offerings globally. The financial results showed a net loss improvement and positive cash flow from continuing operations, reflecting the company’s strategic realignment.
On July 30, 2025, TILT Holdings Inc.’s subsidiary, Standard Farms, LLC, entered into a Management Services Agreement with MariMed Advisors, Inc. to manage its medical marijuana operations in Pennsylvania. The agreement, effective September 1, 2025, includes comprehensive management services such as budgeting, compliance, and financial planning, with a management fee of 12.5% of gross revenue. This strategic move is expected to enhance operational efficiency and compliance, potentially strengthening TILT’s position in the medical marijuana market.